Topics

THERANEXUS: THERANEXUS ANNOUNCES THE CLINICAL RESULTS OF ITS PHASE IB STUDY DEMONSTRATING THE EXTENDED PHARMACOLOGICAL PROFILE OF ITS DRUG CANDIDATE THN201 COMPARED TO DONEPEZIL

12:12 EST 15 Jan 2020 | FinanzNachrichten

Improved speed of memory Significant increase in EEG power in the Gamma band related to cognitive activity Similar profile with respect to other pharmacological, pharmacokinetic and tolerance endp...

Original Article: THERANEXUS: THERANEXUS ANNOUNCES THE CLINICAL RESULTS OF ITS PHASE IB STUDY DEMONSTRATING THE EXTENDED PHARMACOLOGICAL PROFILE OF ITS DRUG CANDIDATE THN201 COMPARED TO DONEPEZIL

NEXT ARTICLE

More From BioPortfolio on "THERANEXUS: THERANEXUS ANNOUNCES THE CLINICAL RESULTS OF ITS PHASE IB STUDY DEMONSTRATING THE EXTENDED PHARMACOLOGICAL PROFILE OF ITS DRUG CANDIDATE THN201 COMPARED TO DONEPEZIL"

Quick Search